Search Results 1891-1900 of 19687 for Hemoglobin

  1. A Study Evaluating Effectiveness and Safety of FFX Versus Combination of CPI-613 with mFFX in Patients with Metastatic Adenocarcinoma of the Pancreas - Mayo Clinic

    Hemoglobin ≥ 9 g/dL or ≥ 90 g/L). Adequate hepatic function: Aspartate aminotransferase [AST/SGOT] ≤ 3x upper normal limit [UNL] Alanine aminotransferase ...

  2. Neurology - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  3. Single arm pilot trial of adaptive therapy (AT) with capecitabine for the treatment of breast cancer - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL, no transfusions allowed ≤ 14 days prior to registration. Absolute neutrophil count (ANC) ≥ 1500/mm3; Platelet count ≥ 100,000/mm3 ...

  4. BCL2 Inhibitor Venetoclax With Daratumumab-Lenalidomide-Dexamethasone Or Venetoclax-Rd for Newly Diagnosed Multiple Myeloma - Mayo Clinic

    * Hemoglobin ≥ 8.0 g/dL (transfusion permitted) (obtained ≤ 14 days prior to registration) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (known ...

  5. Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients with High-Risk Stage III-IV Melanoma that has been Removed by Surgery - Mayo Clinic

    Pregnant or breastfeeding. White blood cell (WBC) ≥ 3,000/uL; Absolute neutrophil count (ANC) ≥ 1,500/uL; Platelets ≥ 100 x 10^3/uL; Hemoglobin ≥ 10 g/dL ...

  6. Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye - Mayo Clinic

    Hemoglobin ≥ 9 g/dL; Serum albumin ≥ 2.8 g/dL; Urine protein/creatinine ratio (UPCR) ≤ 1; if urine/protein creatinine (UPC) ≥ 1, then a 24-hour urine ...

  7. Neurology - Clinical trials - Mayo Clinic

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  8. Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed By Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance In Treatment-Naïve Mantle Cell Lymphoma - Mayo Clinic

    Hemoglobin ≥ 8 g/dL and independent of transfusion within 7 days of screening. Platelets ≥ 100 x109/L, or ≥ 50 x109/L if bone marrow involvement, and ...

  9. Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working - Mayo Clinic

    - Hemoglobin ≥ 9 g/dL (within ≤ 28 days prior to registration). * No transfusions ≤ 14 days before cycle 1 day 1 (C1D1). - Total bilirubin ≤ 1.5 x ULN ...

  10. Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL (within 30 days prior to registration);; Note: The use of transfusion is acceptable; Creatinine clearance (CrCl) > 30 mL/min (within 30 ...